[ 1 ] Colao A, Savastano S. Medical treatment of prolactinomas[J]. Nat Rev Endocrinol, 2011, 7(5): 267-278.
[2]
[ 2 ] Steiger M, Jost W, Grandas F, et al. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review[J]. J Neural Transm, 2009, 116(2): 179-191.
[3]
[ 3 ] Rasmussen VG, stergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists[J]. Mov Disord, 2011, 26(5): 801-806.
[4]
[ 4 ] Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment[J]. Eur J Endocrinol, 2012, 167(1): 17-25.
[5]
[ 5 ] Boguszewski CL, dos Santos CM, Sakamoto KS, et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease inc patients with prolactinomas[J]. Pituitary, 2012, 15(1): 44-49.
[6]
[ 6 ] Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies[J]. J Endocrinol Invest, 2008, 31(12): 1119-1123.
[7]
[ 7 ] Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma[J]. Clin Endocrinol (Oxf), 2009, 70(1): 104-108.
[8]
[ 8 ] Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma[J]. J Clin Endocrinol Metab, 2008, 93(9): 3348-3356.
[9]
[ 9 ] Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline[J]. J Clin Endocrinol Metab, 2008, 93(10): 3777-3784.
[10]
Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia[J]. Clin Endocrinol (Oxf), 2010, 73(3): 369-374.
[11]
Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia[J]. Int J Clin Pract, 2008, 62(12): 1864-1869.
[12]
Halperin I, Aller J, Varela C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma[J]. Clin Endocrinol (Oxf), 2012, 77(2): 275-280.
[13]
Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas[J]. Pituitary, 2009, 12(3): 153-157.
[14]
Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study[J]. Clin Endocrinol (Oxf), 2012, 77(1): 99-105.
